We further outline future perspectives such as hybrid multifunctional nanoplatforms, patient-specific redox profiling, and clinical pathways for regulatory approval
doi: 10.1016/S2468-2667(22)00317-6
Poster Session II - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.02 - ACUTE MANAGEMENT - Thrombolysis or thrombectomy P716 - ESOC25-2036 IMPACT OF ONSET MODE ON TENECTEPLASE FOR ISCHEMIC STROKE AT 4.5 TO 24 HOURS: A POST-HOC ANALYSIS OF THE TRACE-III TRIAL Zhixin Cao 1 , Jinfeng Yin 2 , Liyuan Wang 1 , Manjun Hao 1 , Shuangzhe Wu 1 , Yunyun Xiong 1,2 , Yongjun Wang 1,2 1 Beijing Tiantan Hospital, Capital Medical University, Beijing, China, 2 China National Clinical Research Center for Neurological Diseases, Beijing, China Background and Aims: Whether the efficacy and safety of tenecteplase is different in patients with wake-up and witnessed onset strokes remains uncertain
Assay: Glutathione in human blood
If your solution is cloudy, it may indicate a problem with the peptide's purity or a contamination issue during mixing